Treatment of cancers using anti-NKG2A agents
US11225519B2 · kind B2 · utility
3Cited by
14References
18Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jun 21, 2019 |
| Grant date | Jan 18, 2022 |
| Priority date | — |
| Expiry date | Jun 21, 2039 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/92
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to HLA-E as a tumor escape mechanism in head and neck cancer. The invention relates to methods for the treatment of head and neck cancer, notably HLA-E expressing head and neck squamous cell carcinoma, using antibodies that specifically bind and inhibit human NKG2A.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.